-
Medherant Ltd. Completes £1.5M Fundraising Round for Transdermal Drug Delivery Platform Primary
Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from Mercia Technologies PLC.
-
Bio-start Announces David Lawrence as Competition Finalist Judge
Board member and Head of R&D at one of the world’s largest biotech companies to help select winner of new synthetic biology start-up competition London, UK, 26th September 2016 / Sciad Newswire / SynbiCITE and Rainbow Seed Fund today announce that Dr David Lawrence, Non-executive Director at Syngenta and Chairman of the Science and Technology Advisory Board, will be part of…
-
Quorum Innovations announces availability of human microbiome therapeutics to treat common skin conditions and metabolic disorders
Probiomic Therapeutics™ for Eczema, Atopic Dermatitis, Eosinophilic Esophagitis (EoE), Metabolic Disorders Sarasota, FL, 21st September 2016 / Sciad Newswire / Quorum Innovations has successfully isolated LfQi6 from the human host. Demonstrating strong biofilm formations. Bioactives from LfQi6 have novel bimodal biofilm modulation. Quorum Innovation’s Probiomic Therapeutics™ inhibit and detach pathogenic biofilm while enhancing commensal resident biofilm. Reducing inflammation, promoting inherent defense…
-
Batavia Biosciences Receives Grant to Develop New Vaccine Against Rotavirus
Leiden, The Netherlands, and Woburn, MA, 21st September 2016 / Sciad Newswire / Batavia Biosciences received an $8 million grant from the Bill & Melinda Gates Foundation to develop a low cost manufacturing process to bring an affordable rotavirus vaccine to the global health market. This vaccine aims to save many young children’s lives worldwide. Rotavirus infection, associated with severe…
-
SynbiCITE Announces 4-day MBA for Future Biotechnology Leaders
London, UK, 19th September 2016 / Sciad Newswire / SynbiCITE, in association with the Industrial Biotechnology Innovation Centre (IBiolC) will run another of its 4-Day MBA courses for biotech entrepreneurs in Glasgow from 20-24 November. This interactive course will cover key strategies required to establish, build and manage a biotechnology company and aid in developing the entrepreneurship of future leaders….
-
The 2nd Annual Engineering Biology Awards Recognize Excellence in the Synthetic Biology Industry at SynBioBeta SF 2016
San Francisco, USA, 13th September 2016 / Sciad Newswire / On October 4th-5th, 2016, SynBioBeta will be bringing together the synthetic biology community to recognize excellence in the industry for the 2nd Annual Engineering Biology Awards. The awards are being held at the upcoming SynBioBeta SF 2016 Conference that will be hosted at the South San Francisco Conference Center….
-
Vaccine to Protect Against Sexually Transmitted and Insect-Borne Zika Infections
Keele, UK, 13th September 2016 / Sciad Newswire / Prokarium today announced the start of its programme to develop an oral vaccine against Zika virus infection. Using the Company’s know-how in synthetic biology, the new vaccine will be active against both modes of Zika transmission – insect-borne (antibody-mediated) and sexually transmitted (mucosal and cell-mediated) infections – the first…
-
Prokarium to Develop First Vaccine to Protect Against Sexually Transmitted and Insect-Borne Zika Infections
Keele, UK, 13th September 2016 / Sciad Newswire / Prokarium today announced the start of its programme to develop an oral vaccine against Zika virus infection. Using the Company’s know-how in synthetic biology, the new vaccine will be active against both modes of Zika transmission – insect-borne (antibody-mediated) and sexually transmitted (mucosal and cell-mediated) infections – the first to do…
-
NALIA Systems Files New Patent Applications to Expand Product Range
London, UK, 12th September 2016 / Sciad Newswire / NALIA Systems is pleased to announce the filing of two new patent applications that highlight the continued development of its technology. NALIA is a developer of state-of-the-art multiplex immunodiagnostic systems for clinical management, biomedical research and drug discovery. NALIA’s technology uses multi-biomarker panels in the form of miniaturised ELISA-type tests to…
-
Chesterford Research Park proves ideal new home for Domainex
Saffron Walden, UK, 12th September 2016 / Sciad Newswire / Established in 2001, Domainex is a privately-owned, rapidly-growing drug research company with expertise in expression of disease target proteins, hit discovery, hit-to-lead identification and lead optimisation. It has an established reputation for its high-quality, innovative approach and has a sustained track record of delivering preclinical drug candidates. Domainex has a wide…